Jannsen Biotech, Inc. has filed another motion for a preliminary injunction against Amgen regarding its ustekinemab biosimilar, after its original motion was denied by US District Court Judge Noreika on 2 March 2023. Jannsen is seeking to enjoin Amgen, Inc. from manufacturing and using in commercial quantities, offering to sell, selling within the United States, or importing for commercial purposes into the United States its ABP 654 biosimilar product.
As we previously reported, Judge Noreika had denied Jannsen’s motion because it did not comply with the court’s page limit requirements. Her Honour orally ordered that the motion could be re-filed in compliance with court requirements.
–
Print Page Mail Article